Periop Pembrolizumab’s Results for HNSCC Raise Questions

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and hopes for future innovations. Medscape Medical News

Read the full article on medscape.com